| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
IMCR Stock Overview
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases.
Immunocore Holdings Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$53.69 |
| 52 Week High | US$56.80 |
| 52 Week Low | US$18.43 |
| Beta | 0 |
| 1 Month Change | 24.14% |
| 3 Month Change | 84.19% |
| 1 Year Change | 78.55% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 24.28% |
Recent News & Updates
Need To Know: Analysts Are Much More Bullish On Immunocore Holdings plc (NASDAQ:IMCR)
Celebrations may be in order for Immunocore Holdings plc ( NASDAQ:IMCR ) shareholders, with the analysts delivering a...
Immunocore GAAP EPS of -$0.17, revenue of $38.92M
Immunocore press release (NASDAQ:IMCR): Q2 GAAP EPS of -$0.17. Revenue of $38.92M (+392.7% Y/Y).
Shareholder Returns
| IMCR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.8% | 1.8% | 4.5% |
| 1Y | 78.6% | -22.2% | -8.9% |
Return vs Industry: IMCR exceeded the US Biotechs industry which returned -19.6% over the past year.
Return vs Market: IMCR exceeded the US Market which returned -9.6% over the past year.
Price Volatility
| IMCR volatility | |
|---|---|
| IMCR Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 12.5% |
| Market Average Movement | 7.6% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IMCR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: IMCR's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 324 | Bahija Jallal | https://www.immunocore.com |
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers.
Immunocore Holdings Fundamentals Summary
| IMCR fundamental statistics | |
|---|---|
| Market Cap | US$2.36b |
| Earnings (TTM) | -US$111.04m |
| Revenue (TTM) | US$81.06m |
29.1x
P/S Ratio-21.2x
P/E RatioIs IMCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMCR income statement (TTM) | |
|---|---|
| Revenue | UK£66.99m |
| Cost of Revenue | UK£75.88m |
| Gross Profit | -UK£8.89m |
| Other Expenses | UK£82.88m |
| Earnings | -UK£91.77m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.09 |
| Gross Margin | -13.27% |
| Net Profit Margin | -136.99% |
| Debt/Equity Ratio | 25.2% |
How did IMCR perform over the long term?
See historical performance and comparisonValuation
Is IMCR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IMCR?
Other financial metrics that can be useful for relative valuation.
| What is IMCR's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | UK£1.95b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 27x |
| Enterprise Value/EBITDA | -20.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does IMCR's PS Ratio compare to its peers?
| IMCR PS Ratio vs Peers |
|---|
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 8.2x | ||
MYGN Myriad Genetics | 3.2x | 6.3% | US$2.2b |
CVAC CureVac | 21.5x | 29.0% | US$2.6b |
ACAD ACADIA Pharmaceuticals | 5.4x | 20.8% | US$2.7b |
DVAX Dynavax Technologies | 2.7x | -10.8% | US$1.8b |
IMCR Immunocore Holdings | 29.1x | 29.9% | US$2.4b |
Price-To-Sales vs Peers: IMCR is expensive based on its Price-To-Sales Ratio (29.1x) compared to the peer average (8.2x).
Price to Earnings Ratio vs Industry
How does IMCR's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: IMCR is expensive based on its Price-To-Sales Ratio (29.1x) compared to the US Biotechs industry average (16.9x)
Price to Sales Ratio vs Fair Ratio
What is IMCR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 29.1x |
| Fair PS Ratio | 4.6x |
Price-To-Sales vs Fair Ratio: IMCR is expensive based on its Price-To-Sales Ratio (29.1x) compared to the estimated Fair Price-To-Sales Ratio (4.6x).
Share Price vs Fair Value
What is the Fair Price of IMCR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: IMCR ($53.69) is trading below our estimate of fair value ($159.44)
Significantly Below Fair Value: IMCR is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Future Growth
How is Immunocore Holdings forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score
2/6Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
32.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMCR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IMCR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IMCR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IMCR's revenue (29.9% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: IMCR's revenue (29.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IMCR is forecast to be unprofitable in 3 years.
Discover growth companies
Past Performance
How has Immunocore Holdings performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-13.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IMCR is currently unprofitable.
Growing Profit Margin: IMCR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IMCR is unprofitable, and losses have increased over the past 5 years at a rate of 13.4% per year.
Accelerating Growth: Unable to compare IMCR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMCR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).
Return on Equity
High ROE: IMCR has a negative Return on Equity (-55.74%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Immunocore Holdings's financial position?
Financial Health Score
4/6Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: IMCR's short term assets (£257.1M) exceed its short term liabilities (£64.6M).
Long Term Liabilities: IMCR's short term assets (£257.1M) exceed its long term liabilities (£66.4M).
Debt to Equity History and Analysis
Debt Level: IMCR has more cash than its total debt.
Reducing Debt: IMCR's debt to equity ratio has increased from 5.4% to 25.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IMCR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if IMCR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Dividend
What is Immunocore Holdings's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IMCR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IMCR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IMCR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IMCR's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as IMCR has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
3.0yrs
Average management tenure
CEO
Bahija Jallal (60 yo)
3.58yrs
Tenure
UK£938,226
Compensation
Dr. Bahija Jallal, Ph.D. serves as Chief Executive Officer and Director of Immunocore Holdings plc (formerly known as Immunocore Holdings Limited) since January 4, 2019. She serves as Director at ArriVent...
CEO Compensation Analysis
Compensation vs Market: Bahija's total compensation ($USD1.14M) is below average for companies of similar size in the US market ($USD5.42M).
Compensation vs Earnings: Bahija's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: IMCR's management team is considered experienced (3 years average tenure).
Board Members
Experienced Board: IMCR's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Immunocore Holdings plc's employee growth, exchange listings and data sources
Key Information
- Name: Immunocore Holdings plc
- Ticker: IMCR
- Exchange: NasdaqGS
- Founded: 1999
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$2.357b
- Shares outstanding: 43.90m
- Website: https://www.immunocore.com
Number of Employees
Location
- Immunocore Holdings plc
- 92 Park Drive
- Milton Park
- Abingdon
- Oxfordshire
- OX14 4RY
- United Kingdom
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/16 00:00 |
| End of Day Share Price | 2022/08/16 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.